Reports
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States
Americas
Future Market Insights, Inc.
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States
MEA
Future Market Insights
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom
Asia Pacific
Future Market Insights
IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India
[250 Pages Report] The neurodegenerative disease market is anticipated to register a CAGR of 7% during the forecast period, up from US$ 43.7 Billion in 2021 to reach a valuation of US$ 92 Billion by 2032.
The neurodegenerative disease market is anticipated to show promising growth prospects during the forecasted period due to the increasing frequency of neurological diseases, an aging population, and growing demand for Alzheimer's and Parkinson's disease treatments.
Attributes | Details |
---|---|
Neurodegenerative Disease Market Value (2021) | US$ 43.7 Billion |
Neurodegenerative Disease Market Value (2032) | US$ 92 Billion |
CAGR (2021 to 2032) | 7% |
The neurodegenerative disease market share is expected to grow significantly, mainly due to increasing cases of neurodegenerative disorders. The neurodegenerative disease market is expected to witness advancement in the upcoming years due to a new type of drug launch.
Due to patent protection loss, new players are expected to enter the neurodegenerative disease market during the forecast years. In the Alzheimer’s market, drugs like GABA receptor modulators, anti-amyloid protein agents and nicotinic and cholinergic receptor agonists are expected to influence the neurodegenerative disease market growth.
However, the Parkinson’s disease market will be driven due to the launch of drugs like dopamine receptor agonists and reuptake inhibitors, glutamate receptor modulators, and adrenergic and adenosine antagonists.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The neurodegenerative disease market is expected to thrive as medical technology advances for the detection and rising demand for the treatment of neurodegenerative diseases, increasing the need for neurodegenerative drugs.
The aging population is leading to an increase in the frequency of neurodegenerative diseases, which is one of the primary reasons driving the growth of the neurodegenerative market.
Developing nations, particularly those in the Asia Pacific, are predicted to be strong in the future years.
Growing physician awareness is assisting the neurodegenerative disease market growth to remain in developed countries. Due to the illness's multifaceted character, the lack of comprehensive curative treatment measures might hinder the global neurodegenerative disease market.
The neurodegenerative disease continues to place a significant strain on global healthcare costs and population mental and physical health. All disorders that impact the neurons in the human brain are classified as neurodegenerative diseases.
Alzheimer's disease is the most common neurodegenerative illness, with an estimated 5.8 million instances of Alzheimer's dementia in the United States alone in 2019. Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, Huntington's disease, spinal muscular atrophy, multiple system atrophy, and others are examples of neurodegenerative diseases.
North America generated US$ 18,174.6 Mn in revenue from sales of neurodegenerative diseases drugs in 2018 and is likely to lead the neurodegenerative diseases market during the forecast period.
Growing medication demand, high prices, increased R&D investment, and favorable health reimbursement policies are driving the growth of the neurodegenerative diseases market in North America.
The European neurodegenerative disease market is expected to increase significantly due to the active government backing and marketing clearance for SPINRAZA in June 2017.
The Asia Pacific neurodegenerative diseases drugs market sales are expected to grow at the fastest rate during the forecast period, owing to the rising prevalence of neurodegenerative diseases, an aging population, and increased demand for Alzheimer's and Parkinson's disease drugs in Japan and China.
Some of the key market players in the global neurodegenerative disease market are Novartis, Pfizer, Merck Serono, Biogen Idec, TEVA Pharmaceuticals Industries, UCB, Boehringer Ingelheim, Sanofi S.A., GlaxoSmithKline. Due to patent protection loss, significant players in the neurodegenerative disease market will face competition in the upcoming years.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Report Attributes | Details |
---|---|
Growth rate | CAGR of 7% from 2022 to 2032 |
Base year for estimation | 2021 |
Historical data | 2015 to 2020 |
Forecast period | 2022 to 2032 |
Quantitative units | Revenue in USD million, volume in kilotons, and CAGR from 2022 to 2032 |
Report coverage | Revenue forecast, volume forecast, company ranking, competitive landscape, growth factors, and trends, Pricing Analysis, |
Segments covered | Drug class, disease indication, region |
Regional scope | North America; Western Europe, Eastern Europe, Middle East, Africa, ASEAN, South Asia, Rest of Asia, Australia and New Zealand |
Country scope | U.S.; Canada; Mexico; Germany; U.K.; France; Italy; Spain; Russia; Belgium; Poland; Czech Republic; China; India; Japan; Australia; Brazil; Argentina; Colombia; Saudi Arabia; UAE; Iran; South Africa |
Key companies profiled | Novartis, Pfizer, Merck Serono, Biogen Idec, TEVA Pharmaceuticals Industries, UCB, Boehringer Ingelheim, Sanofi S.A., GlaxoSmithKline |
Customization scope | Free report customization (equivalent to up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options | Avail customized purchase options to meet your exact research needs. |
The neurodegenerative disease market is likely to register a CAGR of 7% during the forecast period.
Key players holding substantial neurodegenerative disease market share include Novartis, Pfizer, Merck Serono, Biogen Idec, TEVA Pharmaceuticals Industries, UCB, Boehringer Ingelheim, Sanofi S.A., GlaxoSmithKline
As per the analysis, the neurodegenerative disease market share is likely to be US$ 92 Bn by 2032.
Demand for neurodegenerative disease treatment is likely to rise due to increasing prevalence of neurological diseases, an ageing population, and an increase in demand for Alzheimer's and Parkinson's disease treatments.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2017-2021 and Forecast, 2022-2032 4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021 4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Disease Indication 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Mn) Analysis By Disease Indication, 2017-2021 5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Disease Indication, 2022-2032 5.3.1. Alzheimer’s Disease 5.3.2. Motor Neuron Diseases 5.3.3. Parkinson’s Disease 5.3.4. Huntington’s Disease 5.3.5. Multiple Sclerosis 5.3.6. Others 5.4. Y-o-Y Growth Trend Analysis By Disease Indication, 2017-2021 5.5. Absolute $ Opportunity Analysis By Disease Indication, 2022-2032 Deep-dive segmentation will be available in the sample on request 6. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Drug Class 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Mn) Analysis By Drug Class, 2017-2021 6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Drug Class, 2022-2032 6.3.1. Cholinesterase Inhibitors 6.3.2. Dopamine Inhibitors 6.3.3. MAO-B Inhibitors 6.3.4. Catechol-O-methyltransferase Inhibitors 6.3.5. Anticholinergics 6.3.6. Antipsychotic Drugs 6.3.7. Dopamine Antagonists 6.3.8. Others 6.4. Y-o-Y Growth Trend Analysis By Drug Class, 2017-2021 6.5. Absolute $ Opportunity Analysis By Drug Class, 2022-2032 Deep-dive segmentation will be available in the sample on request 7. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Route of Administration 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Mn) Analysis By Route of Administration, 2017-2021 7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Route of Administration, 2022-2032 7.3.1. Oral Drugs 7.3.2. Parenteral Drugs 7.3.3. Topical Drugs 7.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2017-2021 7.5. Absolute $ Opportunity Analysis By Route of Administration, 2022-2032 Deep-dive segmentation will be available in the sample on request 8. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Distribution Channel 8.1. Introduction / Key Findings 8.2. Historical Market Size Value (US$ Mn) Analysis By Distribution Channel, 2017-2021 8.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Distribution Channel, 2022-2032 8.3.1. Hospital Pharmacies 8.3.2. Retail Pharmacies 8.3.3. Online Pharmacies 8.3.4. Drug Stores 8.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2017-2021 8.5. Absolute $ Opportunity Analysis By Distribution Channel, 2022-2032 Deep-dive segmentation will be available in the sample on request 9. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Region 9.1. Introduction 9.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2017-2021 9.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032 9.3.1. North America 9.3.2. Latin America 9.3.3. Europe 9.3.4. East Asia 9.3.5. South Asia & Pacific 9.3.6. MEA 9.4. Market Attractiveness Analysis By Region 10. North America Market Analysis 2017-2021 and Forecast 2022-2032, By Country 10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 10.2.1. By Country 10.2.1.1. U.K. 10.2.1.2. Canada 10.2.2. By Disease Indication 10.2.3. By Drug Class 10.2.4. By Route of Administration 10.2.5. By Distribution Channel 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Disease Indication 10.3.3. By Drug Class 10.3.4. By Route of Administration 10.3.5. By Distribution Channel 10.4. Key Takeaways 11. Latin America Market Analysis 2017-2021 and Forecast 2022-2032, By Country 11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 11.2.1. By Country 11.2.1.1. Brazil 11.2.1.2. Mexico 11.2.1.3. Rest of Latin America 11.2.2. By Disease Indication 11.2.3. By Drug Class 11.2.4. By Route of Administration 11.2.5. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Disease Indication 11.3.3. By Drug Class 11.3.4. By Route of Administration 11.3.5. By Distribution Channel 11.4. Key Takeaways 12. Europe Market Analysis 2017-2021 and Forecast 2022-2032, By Country 12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 12.2.1. By Country 12.2.1.1. Germany 12.2.1.2. U.K. 12.2.1.3. France 12.2.1.4. Spain 12.2.1.5. Italy 12.2.1.6. Rest of Europe 12.2.2. By Disease Indication 12.2.3. By Drug Class 12.2.4. By Route of Administration 12.2.5. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Disease Indication 12.3.3. By Drug Class 12.3.4. By Route of Administration 12.3.5. By Distribution Channel 12.4. Key Takeaways 13. East Asia Market Analysis 2017-2021 and Forecast 2022-2032, By Country 13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 13.2.1. By Country 13.2.1.1. China 13.2.1.2. Japan 13.2.1.3. South Korea 13.2.2. By Disease Indication 13.2.3. By Drug Class 13.2.4. By Route of Administration 13.2.5. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Disease Indication 13.3.3. By Drug Class 13.3.4. By Route of Administration 13.3.5. By Distribution Channel 13.4. Key Takeaways 14. South Asia & Pacific Market Analysis 2017-2021 and Forecast 2022-2032, By Country 14.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 14.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 14.2.1. By Country 14.2.1.1. India 14.2.1.2. Thailand 14.2.1.3. Indonesia 14.2.1.4. Malaysia 14.2.1.5. Singapore 14.2.1.6. Australia 14.2.1.7. New Zealand 14.2.1.8. Rest of South Asia & Pacific 14.2.2. By Disease Indication 14.2.3. By Drug Class 14.2.4. By Route of Administration 14.2.5. By Distribution Channel 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Disease Indication 14.3.3. By Drug Class 14.3.4. By Route of Administration 14.3.5. By Distribution Channel 14.4. Key Takeaways 15. MEA Market Analysis 2017-2021 and Forecast 2022-2032, By Country 15.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 15.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 15.2.1. By Country 15.2.1.1. GCC Countries 15.2.1.2. South Africa 15.2.1.3. Israel 15.2.1.4. Rest of MEA 15.2.2. By Disease Indication 15.2.3. By Drug Class 15.2.4. By Route of Administration 15.2.5. By Distribution Channel 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Disease Indication 15.3.3. By Drug Class 15.3.4. By Route of Administration 15.3.5. By Distribution Channel 15.4. Key Takeaways 16. Key Countries Market Analysis 16.1. U.K. 16.1.1. Pricing Analysis 16.1.2. Market Share Analysis, 2021 16.1.2.1. By Disease Indication 16.1.2.2. By Drug Class 16.1.2.3. By Route of Administration 16.1.2.4. By Distribution Channel 16.2. Canada 16.2.1. Pricing Analysis 16.2.2. Market Share Analysis, 2021 16.2.2.1. By Disease Indication 16.2.2.2. By Drug Class 16.2.2.3. By Route of Administration 16.2.2.4. By Distribution Channel 16.3. Brazil 16.3.1. Pricing Analysis 16.3.2. Market Share Analysis, 2021 16.3.2.1. By Disease Indication 16.3.2.2. By Drug Class 16.3.2.3. By Route of Administration 16.3.2.4. By Distribution Channel 16.4. Mexico 16.4.1. Pricing Analysis 16.4.2. Market Share Analysis, 2021 16.4.2.1. By Disease Indication 16.4.2.2. By Drug Class 16.4.2.3. By Route of Administration 16.4.2.4. By Distribution Channel 16.5. Germany 16.5.1. Pricing Analysis 16.5.2. Market Share Analysis, 2021 16.5.2.1. By Disease Indication 16.5.2.2. By Drug Class 16.5.2.3. By Route of Administration 16.5.2.4. By Distribution Channel 16.6. U.K. 16.6.1. Pricing Analysis 16.6.2. Market Share Analysis, 2021 16.6.2.1. By Disease Indication 16.6.2.2. By Drug Class 16.6.2.3. By Route of Administration 16.6.2.4. By Distribution Channel 16.7. France 16.7.1. Pricing Analysis 16.7.2. Market Share Analysis, 2021 16.7.2.1. By Disease Indication 16.7.2.2. By Drug Class 16.7.2.3. By Route of Administration 16.7.2.4. By Distribution Channel 16.8. Spain 16.8.1. Pricing Analysis 16.8.2. Market Share Analysis, 2021 16.8.2.1. By Disease Indication 16.8.2.2. By Drug Class 16.8.2.3. By Route of Administration 16.8.2.4. By Distribution Channel 16.9. Italy 16.9.1. Pricing Analysis 16.9.2. Market Share Analysis, 2021 16.9.2.1. By Disease Indication 16.9.2.2. By Drug Class 16.9.2.3. By Route of Administration 16.9.2.4. By Distribution Channel 16.10. China 16.10.1. Pricing Analysis 16.10.2. Market Share Analysis, 2021 16.10.2.1. By Disease Indication 16.10.2.2. By Drug Class 16.10.2.3. By Route of Administration 16.10.2.4. By Distribution Channel 16.11. Japan 16.11.1. Pricing Analysis 16.11.2. Market Share Analysis, 2021 16.11.2.1. By Disease Indication 16.11.2.2. By Drug Class 16.11.2.3. By Route of Administration 16.11.2.4. By Distribution Channel 16.12. South Korea 16.12.1. Pricing Analysis 16.12.2. Market Share Analysis, 2021 16.12.2.1. By Disease Indication 16.12.2.2. By Drug Class 16.12.2.3. By Route of Administration 16.12.2.4. By Distribution Channel 16.13. India 16.13.1. Pricing Analysis 16.13.2. Market Share Analysis, 2021 16.13.2.1. By Disease Indication 16.13.2.2. By Drug Class 16.13.2.3. By Route of Administration 16.13.2.4. By Distribution Channel 16.14. Thailand 16.14.1. Pricing Analysis 16.14.2. Market Share Analysis, 2021 16.14.2.1. By Disease Indication 16.14.2.2. By Drug Class 16.14.2.3. By Route of Administration 16.14.2.4. By Distribution Channel 16.15. Indonesia 16.15.1. Pricing Analysis 16.15.2. Market Share Analysis, 2021 16.15.2.1. By Disease Indication 16.15.2.2. By Drug Class 16.15.2.3. By Route of Administration 16.15.2.4. By Distribution Channel 16.16. Malaysia 16.16.1. Pricing Analysis 16.16.2. Market Share Analysis, 2021 16.16.2.1. By Disease Indication 16.16.2.2. By Drug Class 16.16.2.3. By Route of Administration 16.16.2.4. By Distribution Channel 16.17. Singapore 16.17.1. Pricing Analysis 16.17.2. Market Share Analysis, 2021 16.17.2.1. By Disease Indication 16.17.2.2. By Drug Class 16.17.2.3. By Route of Administration 16.17.2.4. By Distribution Channel 16.18. Australia 16.18.1. Pricing Analysis 16.18.2. Market Share Analysis, 2021 16.18.2.1. By Disease Indication 16.18.2.2. By Drug Class 16.18.2.3. By Route of Administration 16.18.2.4. By Distribution Channel 16.19. New Zealand 16.19.1. Pricing Analysis 16.19.2. Market Share Analysis, 2021 16.19.2.1. By Disease Indication 16.19.2.2. By Drug Class 16.19.2.3. By Route of Administration 16.19.2.4. By Distribution Channel 16.20. GCC Countries 16.20.1. Pricing Analysis 16.20.2. Market Share Analysis, 2021 16.20.2.1. By Disease Indication 16.20.2.2. By Drug Class 16.20.2.3. By Route of Administration 16.20.2.4. By Distribution Channel 16.21. South Africa 16.21.1. Pricing Analysis 16.21.2. Market Share Analysis, 2021 16.21.2.1. By Disease Indication 16.21.2.2. By Drug Class 16.21.2.3. By Route of Administration 16.21.2.4. By Distribution Channel 16.22. Israel 16.22.1. Pricing Analysis 16.22.2. Market Share Analysis, 2021 16.22.2.1. By Disease Indication 16.22.2.2. By Drug Class 16.22.2.3. By Route of Administration 16.22.2.4. By Distribution Channel 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Disease Indication 17.3.3. By Drug Class 17.3.4. By Route of Administration 17.3.5. By Distribution Channel 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. F. Hoffmann-La Roche Ltd 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.2. Novartis AG 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.3. Biogen 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.4. Teva Pharmaceuticals Industries Ltd. 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.5. Eisai Co., Ltd. 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.6. Sanofi 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.7. Merck KGaA 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.8. UCB S.A 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.9. Boehringer Ingelheim International GmbH 18.1.9.1. Overview 18.1.9.2. Product Portfolio 18.1.9.3. Profitability by Market Segments 18.1.9.4. Sales Footprint 18.1.9.5. Strategy Overview 18.1.9.5.1. Marketing Strategy 18.1.10. GlaxoSmithKline plc 18.1.10.1. Overview 18.1.10.2. Product Portfolio 18.1.10.3. Profitability by Market Segments 18.1.10.4. Sales Footprint 18.1.10.5. Strategy Overview 18.1.10.5.1. Marketing Strategy 18.1.11. Neuro-Hitech, Inc. 18.1.11.1. Overview 18.1.11.2. Product Portfolio 18.1.11.3. Profitability by Market Segments 18.1.11.4. Sales Footprint 18.1.11.5. Strategy Overview 18.1.11.5.1. Marketing Strategy 18.1.12. BioVision Inc 18.1.12.1. Overview 18.1.12.2. Product Portfolio 18.1.12.3. Profitability by Market Segments 18.1.12.4. Sales Footprint 18.1.12.5. Strategy Overview 18.1.12.5.1. Marketing Strategy 18.1.13. Aquinnah Pharmaceuticals 18.1.13.1. Overview 18.1.13.2. Product Portfolio 18.1.13.3. Profitability by Market Segments 18.1.13.4. Sales Footprint 18.1.13.5. Strategy Overview 18.1.13.5.1. Marketing Strategy 18.1.14. ADDEX THERAPEUTICS 18.1.14.1. Overview 18.1.14.2. Product Portfolio 18.1.14.3. Profitability by Market Segments 18.1.14.4. Sales Footprint 18.1.14.5. Strategy Overview 18.1.14.5.1. Marketing Strategy 18.1.15. Cellcentric 18.1.15.1. Overview 18.1.15.2. Product Portfolio 18.1.15.3. Profitability by Market Segments 18.1.15.4. Sales Footprint 18.1.15.5. Strategy Overview 18.1.15.5.1. Marketing Strategy 18.1.16. Mission Therapeutics 18.1.16.1. Overview 18.1.16.2. Product Portfolio 18.1.16.3. Profitability by Market Segments 18.1.16.4. Sales Footprint 18.1.16.5. Strategy Overview 18.1.16.5.1. Marketing Strategy 18.1.17. CogRx 18.1.17.1. Overview 18.1.17.2. Product Portfolio 18.1.17.3. Profitability by Market Segments 18.1.17.4. Sales Footprint 18.1.17.5. Strategy Overview 18.1.17.5.1. Marketing Strategy 18.1.18. Denali Therapeutics Inc 18.1.18.1. Overview 18.1.18.2. Product Portfolio 18.1.18.3. Profitability by Market Segments 18.1.18.4. Sales Footprint 18.1.18.5. Strategy Overview 18.1.18.5.1. Marketing Strategy 18.1.19. Psyadon Pharmaceuticals, Inc. 18.1.19.1. Overview 18.1.19.2. Product Portfolio 18.1.19.3. Profitability by Market Segments 18.1.19.4. Sales Footprint 18.1.19.5. Strategy Overview 18.1.19.5.1. Marketing Strategy 18.1.20. Cipla Inc. 18.1.20.1. Overview 18.1.20.2. Product Portfolio 18.1.20.3. Profitability by Market Segments 18.1.20.4. Sales Footprint 18.1.20.5. Strategy Overview 18.1.20.5.1. Marketing Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
Table 1: Global Market Value (US$ Mn) Forecast by Region, 2017-2032 Table 2: Global Market Value (US$ Mn) Forecast by Disease Indication, 2017-2032 Table 3: Global Market Value (US$ Mn) Forecast by Drug Class, 2017-2032 Table 4: Global Market Value (US$ Mn) Forecast by Route of Administration, 2017-2032 Table 5: Global Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032 Table 6: North America Market Value (US$ Mn) Forecast by Country, 2017-2032 Table 7: North America Market Value (US$ Mn) Forecast by Disease Indication, 2017-2032 Table 8: North America Market Value (US$ Mn) Forecast by Drug Class, 2017-2032 Table 9: North America Market Value (US$ Mn) Forecast by Route of Administration, 2017-2032 Table 10: North America Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032 Table 11: Latin America Market Value (US$ Mn) Forecast by Country, 2017-2032 Table 12: Latin America Market Value (US$ Mn) Forecast by Disease Indication, 2017-2032 Table 13: Latin America Market Value (US$ Mn) Forecast by Drug Class, 2017-2032 Table 14: Latin America Market Value (US$ Mn) Forecast by Route of Administration, 2017-2032 Table 15: Latin America Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032 Table 16: Europe Market Value (US$ Mn) Forecast by Country, 2017-2032 Table 17: Europe Market Value (US$ Mn) Forecast by Disease Indication, 2017-2032 Table 18: Europe Market Value (US$ Mn) Forecast by Drug Class, 2017-2032 Table 19: Europe Market Value (US$ Mn) Forecast by Route of Administration, 2017-2032 Table 20: Europe Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032 Table 21: East Asia Market Value (US$ Mn) Forecast by Country, 2017-2032 Table 22: East Asia Market Value (US$ Mn) Forecast by Disease Indication, 2017-2032 Table 23: East Asia Market Value (US$ Mn) Forecast by Drug Class, 2017-2032 Table 24: East Asia Market Value (US$ Mn) Forecast by Route of Administration, 2017-2032 Table 25: East Asia Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032 Table 26: South Asia & Pacific Market Value (US$ Mn) Forecast by Country, 2017-2032 Table 27: South Asia & Pacific Market Value (US$ Mn) Forecast by Disease Indication, 2017-2032 Table 28: South Asia & Pacific Market Value (US$ Mn) Forecast by Drug Class, 2017-2032 Table 29: South Asia & Pacific Market Value (US$ Mn) Forecast by Route of Administration, 2017-2032 Table 30: South Asia & Pacific Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032 Table 31: MEA Market Value (US$ Mn) Forecast by Country, 2017-2032 Table 32: MEA Market Value (US$ Mn) Forecast by Disease Indication, 2017-2032 Table 33: MEA Market Value (US$ Mn) Forecast by Drug Class, 2017-2032 Table 34: MEA Market Value (US$ Mn) Forecast by Route of Administration, 2017-2032 Table 35: MEA Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032
Figure 1: Global Market Value (US$ Mn) by Disease Indication, 2022-2032 Figure 2: Global Market Value (US$ Mn) by Drug Class, 2022-2032 Figure 3: Global Market Value (US$ Mn) by Route of Administration, 2022-2032 Figure 4: Global Market Value (US$ Mn) by Distribution Channel, 2022-2032 Figure 5: Global Market Value (US$ Mn) by Region, 2022-2032 Figure 6: Global Market Value (US$ Mn) Analysis by Region, 2017-2032 Figure 7: Global Market Value Share (%) and BPS Analysis by Region, 2022-2032 Figure 8: Global Market Y-o-Y Growth (%) Projections by Region, 2022-2032 Figure 9: Global Market Value (US$ Mn) Analysis by Disease Indication, 2017-2032 Figure 10: Global Market Value Share (%) and BPS Analysis by Disease Indication, 2022-2032 Figure 11: Global Market Y-o-Y Growth (%) Projections by Disease Indication, 2022-2032 Figure 12: Global Market Value (US$ Mn) Analysis by Drug Class, 2017-2032 Figure 13: Global Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032 Figure 14: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032 Figure 15: Global Market Value (US$ Mn) Analysis by Route of Administration, 2017-2032 Figure 16: Global Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032 Figure 17: Global Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032 Figure 18: Global Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032 Figure 19: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032 Figure 20: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032 Figure 21: Global Market Attractiveness by Disease Indication, 2022-2032 Figure 22: Global Market Attractiveness by Drug Class, 2022-2032 Figure 23: Global Market Attractiveness by Route of Administration, 2022-2032 Figure 24: Global Market Attractiveness by Distribution Channel, 2022-2032 Figure 25: Global Market Attractiveness by Region, 2022-2032 Figure 26: North America Market Value (US$ Mn) by Disease Indication, 2022-2032 Figure 27: North America Market Value (US$ Mn) by Drug Class, 2022-2032 Figure 28: North America Market Value (US$ Mn) by Route of Administration, 2022-2032 Figure 29: North America Market Value (US$ Mn) by Distribution Channel, 2022-2032 Figure 30: North America Market Value (US$ Mn) by Country, 2022-2032 Figure 31: North America Market Value (US$ Mn) Analysis by Country, 2017-2032 Figure 32: North America Market Value Share (%) and BPS Analysis by Country, 2022-2032 Figure 33: North America Market Y-o-Y Growth (%) Projections by Country, 2022-2032 Figure 34: North America Market Value (US$ Mn) Analysis by Disease Indication, 2017-2032 Figure 35: North America Market Value Share (%) and BPS Analysis by Disease Indication, 2022-2032 Figure 36: North America Market Y-o-Y Growth (%) Projections by Disease Indication, 2022-2032 Figure 37: North America Market Value (US$ Mn) Analysis by Drug Class, 2017-2032 Figure 38: North America Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032 Figure 39: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032 Figure 40: North America Market Value (US$ Mn) Analysis by Route of Administration, 2017-2032 Figure 41: North America Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032 Figure 42: North America Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032 Figure 43: North America Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032 Figure 44: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032 Figure 45: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032 Figure 46: North America Market Attractiveness by Disease Indication, 2022-2032 Figure 47: North America Market Attractiveness by Drug Class, 2022-2032 Figure 48: North America Market Attractiveness by Route of Administration, 2022-2032 Figure 49: North America Market Attractiveness by Distribution Channel, 2022-2032 Figure 50: North America Market Attractiveness by Country, 2022-2032 Figure 51: Latin America Market Value (US$ Mn) by Disease Indication, 2022-2032 Figure 52: Latin America Market Value (US$ Mn) by Drug Class, 2022-2032 Figure 53: Latin America Market Value (US$ Mn) by Route of Administration, 2022-2032 Figure 54: Latin America Market Value (US$ Mn) by Distribution Channel, 2022-2032 Figure 55: Latin America Market Value (US$ Mn) by Country, 2022-2032 Figure 56: Latin America Market Value (US$ Mn) Analysis by Country, 2017-2032 Figure 57: Latin America Market Value Share (%) and BPS Analysis by Country, 2022-2032 Figure 58: Latin America Market Y-o-Y Growth (%) Projections by Country, 2022-2032 Figure 59: Latin America Market Value (US$ Mn) Analysis by Disease Indication, 2017-2032 Figure 60: Latin America Market Value Share (%) and BPS Analysis by Disease Indication, 2022-2032 Figure 61: Latin America Market Y-o-Y Growth (%) Projections by Disease Indication, 2022-2032 Figure 62: Latin America Market Value (US$ Mn) Analysis by Drug Class, 2017-2032 Figure 63: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032 Figure 64: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032 Figure 65: Latin America Market Value (US$ Mn) Analysis by Route of Administration, 2017-2032 Figure 66: Latin America Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032 Figure 67: Latin America Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032 Figure 68: Latin America Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032 Figure 69: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032 Figure 70: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032 Figure 71: Latin America Market Attractiveness by Disease Indication, 2022-2032 Figure 72: Latin America Market Attractiveness by Drug Class, 2022-2032 Figure 73: Latin America Market Attractiveness by Route of Administration, 2022-2032 Figure 74: Latin America Market Attractiveness by Distribution Channel, 2022-2032 Figure 75: Latin America Market Attractiveness by Country, 2022-2032 Figure 76: Europe Market Value (US$ Mn) by Disease Indication, 2022-2032 Figure 77: Europe Market Value (US$ Mn) by Drug Class, 2022-2032 Figure 78: Europe Market Value (US$ Mn) by Route of Administration, 2022-2032 Figure 79: Europe Market Value (US$ Mn) by Distribution Channel, 2022-2032 Figure 80: Europe Market Value (US$ Mn) by Country, 2022-2032 Figure 81: Europe Market Value (US$ Mn) Analysis by Country, 2017-2032 Figure 82: Europe Market Value Share (%) and BPS Analysis by Country, 2022-2032 Figure 83: Europe Market Y-o-Y Growth (%) Projections by Country, 2022-2032 Figure 84: Europe Market Value (US$ Mn) Analysis by Disease Indication, 2017-2032 Figure 85: Europe Market Value Share (%) and BPS Analysis by Disease Indication, 2022-2032 Figure 86: Europe Market Y-o-Y Growth (%) Projections by Disease Indication, 2022-2032 Figure 87: Europe Market Value (US$ Mn) Analysis by Drug Class, 2017-2032 Figure 88: Europe Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032 Figure 89: Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032 Figure 90: Europe Market Value (US$ Mn) Analysis by Route of Administration, 2017-2032 Figure 91: Europe Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032 Figure 92: Europe Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032 Figure 93: Europe Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032 Figure 94: Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032 Figure 95: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032 Figure 96: Europe Market Attractiveness by Disease Indication, 2022-2032 Figure 97: Europe Market Attractiveness by Drug Class, 2022-2032 Figure 98: Europe Market Attractiveness by Route of Administration, 2022-2032 Figure 99: Europe Market Attractiveness by Distribution Channel, 2022-2032 Figure 100: Europe Market Attractiveness by Country, 2022-2032 Figure 101: East Asia Market Value (US$ Mn) by Disease Indication, 2022-2032 Figure 102: East Asia Market Value (US$ Mn) by Drug Class, 2022-2032 Figure 103: East Asia Market Value (US$ Mn) by Route of Administration, 2022-2032 Figure 104: East Asia Market Value (US$ Mn) by Distribution Channel, 2022-2032 Figure 105: East Asia Market Value (US$ Mn) by Country, 2022-2032 Figure 106: East Asia Market Value (US$ Mn) Analysis by Country, 2017-2032 Figure 107: East Asia Market Value Share (%) and BPS Analysis by Country, 2022-2032 Figure 108: East Asia Market Y-o-Y Growth (%) Projections by Country, 2022-2032 Figure 109: East Asia Market Value (US$ Mn) Analysis by Disease Indication, 2017-2032 Figure 110: East Asia Market Value Share (%) and BPS Analysis by Disease Indication, 2022-2032 Figure 111: East Asia Market Y-o-Y Growth (%) Projections by Disease Indication, 2022-2032 Figure 112: East Asia Market Value (US$ Mn) Analysis by Drug Class, 2017-2032 Figure 113: East Asia Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032 Figure 114: East Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032 Figure 115: East Asia Market Value (US$ Mn) Analysis by Route of Administration, 2017-2032 Figure 116: East Asia Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032 Figure 117: East Asia Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032 Figure 118: East Asia Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032 Figure 119: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032 Figure 120: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032 Figure 121: East Asia Market Attractiveness by Disease Indication, 2022-2032 Figure 122: East Asia Market Attractiveness by Drug Class, 2022-2032 Figure 123: East Asia Market Attractiveness by Route of Administration, 2022-2032 Figure 124: East Asia Market Attractiveness by Distribution Channel, 2022-2032 Figure 125: East Asia Market Attractiveness by Country, 2022-2032 Figure 126: South Asia & Pacific Market Value (US$ Mn) by Disease Indication, 2022-2032 Figure 127: South Asia & Pacific Market Value (US$ Mn) by Drug Class, 2022-2032 Figure 128: South Asia & Pacific Market Value (US$ Mn) by Route of Administration, 2022-2032 Figure 129: South Asia & Pacific Market Value (US$ Mn) by Distribution Channel, 2022-2032 Figure 130: South Asia & Pacific Market Value (US$ Mn) by Country, 2022-2032 Figure 131: South Asia & Pacific Market Value (US$ Mn) Analysis by Country, 2017-2032 Figure 132: South Asia & Pacific Market Value Share (%) and BPS Analysis by Country, 2022-2032 Figure 133: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Country, 2022-2032 Figure 134: South Asia & Pacific Market Value (US$ Mn) Analysis by Disease Indication, 2017-2032 Figure 135: South Asia & Pacific Market Value Share (%) and BPS Analysis by Disease Indication, 2022-2032 Figure 136: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Disease Indication, 2022-2032 Figure 137: South Asia & Pacific Market Value (US$ Mn) Analysis by Drug Class, 2017-2032 Figure 138: South Asia & Pacific Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032 Figure 139: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032 Figure 140: South Asia & Pacific Market Value (US$ Mn) Analysis by Route of Administration, 2017-2032 Figure 141: South Asia & Pacific Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032 Figure 142: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032 Figure 143: South Asia & Pacific Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032 Figure 144: South Asia & Pacific Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032 Figure 145: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032 Figure 146: South Asia & Pacific Market Attractiveness by Disease Indication, 2022-2032 Figure 147: South Asia & Pacific Market Attractiveness by Drug Class, 2022-2032 Figure 148: South Asia & Pacific Market Attractiveness by Route of Administration, 2022-2032 Figure 149: South Asia & Pacific Market Attractiveness by Distribution Channel, 2022-2032 Figure 150: South Asia & Pacific Market Attractiveness by Country, 2022-2032 Figure 151: MEA Market Value (US$ Mn) by Disease Indication, 2022-2032 Figure 152: MEA Market Value (US$ Mn) by Drug Class, 2022-2032 Figure 153: MEA Market Value (US$ Mn) by Route of Administration, 2022-2032 Figure 154: MEA Market Value (US$ Mn) by Distribution Channel, 2022-2032 Figure 155: MEA Market Value (US$ Mn) by Country, 2022-2032 Figure 156: MEA Market Value (US$ Mn) Analysis by Country, 2017-2032 Figure 157: MEA Market Value Share (%) and BPS Analysis by Country, 2022-2032 Figure 158: MEA Market Y-o-Y Growth (%) Projections by Country, 2022-2032 Figure 159: MEA Market Value (US$ Mn) Analysis by Disease Indication, 2017-2032 Figure 160: MEA Market Value Share (%) and BPS Analysis by Disease Indication, 2022-2032 Figure 161: MEA Market Y-o-Y Growth (%) Projections by Disease Indication, 2022-2032 Figure 162: MEA Market Value (US$ Mn) Analysis by Drug Class, 2017-2032 Figure 163: MEA Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032 Figure 164: MEA Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032 Figure 165: MEA Market Value (US$ Mn) Analysis by Route of Administration, 2017-2032 Figure 166: MEA Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032 Figure 167: MEA Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032 Figure 168: MEA Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032 Figure 169: MEA Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032 Figure 170: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032 Figure 171: MEA Market Attractiveness by Disease Indication, 2022-2032 Figure 172: MEA Market Attractiveness by Drug Class, 2022-2032 Figure 173: MEA Market Attractiveness by Route of Administration, 2022-2032 Figure 174: MEA Market Attractiveness by Distribution Channel, 2022-2032 Figure 175: MEA Market Attractiveness by Country, 2022-2032
Recommendations
Explore Healthcare Insights
View Reports